Clinical trial · Observational
Use of Molecular Breast Imaging (MBI) to Detect Additional Disease in Women With Breast Cancer Who Are About to go to Surgery
Molecular Breast Imaging in the Preoperative Evaluation of Women With Biopsy Proven Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Conventional mammography is not a reliable method for determining the extent of disease in women with breast cancer. Molecular Breast Imaging (MBI) is a new nuclear medicine technique that allows the breast to be imaged in a manner similar to mammography, but without the pain of compression. Initial results with this method have shown it is very good at detecting small breast cancers (\~1/4 inch). The purpose of this study is to see if MBI is a better method than mammography in determining how much cancer is present before a woman goes to surgery. The study will comprise 120 women with breast cancer who are going to surgery. The investigators hope that this study will demonstrate that MBI will be more accurate in determining how much cancer is present.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The gold standard for assessing MBI will be tissue pathology. Using pathology as the gold standard, we will compare the sensitivity of MBI to that of mammography in the evaluation of this patient population.
- timeFrame
- At surgery
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 25 Years
Show eligibility criteria text
Inclusion Criteria: * Women with biopsy-proven breast cancer (invasive breast cancer or ductal carcinoma in situ) Exclusion Criteria: * Unable to understand and sign the consent form * Pregnant or lactating * Physically unable to sit upright and still for 40 minutes * Currently receiving neoadjuvant chemotherapy or hormonal therapy * Currently taking tamoxifen, evista (raloxifene), or an aromatase inhibitor * Previous mastectomy * Previous excisional biopsy of the index breast cancer
References
Publications (0)
Data not yet available